Health experts say figures are ‘extremely concerning’ and warn of increased risk of diabetes, cancer and mental health issues
US judge declines to intervene in fray because process ‘is creating value for Metsera stockholders’
Council-commissioned providers are fast losing headroom needed to improve pay and compete with other employers
Plus, inside the super secretive intelligence firm Black Cube and Pfizer takes no prisoners in its fight to buy Metsera
US pharma group says region’s use of ‘one-way insurance system’ to keep down prices is not fair on the industry
Pfizer has filed two lawsuits to block Novo Nordisk’s $9bn bid to buy Metsera
Reforming the benefits system is vital to avoid ever-rising taxes
Novo and Metsera deny Pfizer’s arguments
Move by FTSE’s biggest company gains support of 99% of shareholders who voted in blow to London market
$49bn tie-up comes on frantic day of mergers and acquisitions across corporate America
Research using data from Harvard Aging Brain Study showed more active patients saw slower cognitive deterioration
Contrasting data points to gains in parts of health service not extending across wider sector
Just how many really count?
FTC fast-tracks antitrust approval of earlier deal in sign Washington could weigh in on takeover battle with Novo Nordisk
Pharma group boosts financial outlook as revenues from flagship medicines leap
Buyout bosses intend to contest any attempt by competition watchdog to disqualify them as directors of British companies
Bid for drugmaker Metsera is unusually aggressive in terms of price, timing and structure
Pfizer had struck deal in September to buy obesity-focused biotech
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of obesity medicine
Move is latest broadside by Trump administration against pharmaceuticals industry that fought to derail changes
Deal for software group marks one of the biggest private equity exits of the year
World Health Organization’s priorities tilted by reliance on charitable foundation, according to research
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
A former New York Times reporter accuses the US company of corporate gaslighting on an epic scale in his book ‘No More Tears’
Record utilities deal and regional bank takeover are latest sign of consolidation bout in key sectors
